IN THE CLAIMS

Claim 1(original): A method of treating anorexia nervosa, bulimia and related clinical syndromes by administering eicosapentaenoic acid (EPA) in any appropriate form which can be assimilated by the body.

Claim 2(original): Use of eicosapentaenoic acid (EPA) in any appropriate form which can be assimilated by the body in the manufacture of a medicament for the treatment of anorexia nervosa, bulimia and related clinical syndromes.

Claim 3(currently amended): A method according to claim 1 ~~or use according to claim 2~~, in which the EPA is from a natural EPA-containing oil.

Claim 4(currently amended): A method according to claim 1 ~~or use according to claim 2~~, in which the EPA is in the form of the free acid, an appropriate salt, a mono-, di-, or triglyceride, a phospholipid, an amide, an ester or any other biologically compatible derivative.

Claim 5(currently amended): A method according to claim 1 ~~or use according to claim 2~~, in which the EPA is in the form of the triglyceride or the ethyl ester.

Claim 6(currently amended): A method or use according to claim 1, ~~2, 4 or 5~~, in which the EPA is more than 70%, preferably more than 90% and very preferably more than 95% pure.

Claim 7(original): A method or use according to claim 6, in which the EPA contains less than 10% in aggregate and less than 3% individually of docosahexaenoic acid, linoleic acid and arachidonic acid.

Claim 8(original): A method or use according to claim 6, in which the EPA contains less than 5% in aggregate and less than 2% individually of docosahexaenoic acid and linoleic acid.

Claim 9(currently amended): A method or use according to claim 7 ~~claims 7 or 8~~, in which the EPA is in the form of the ethyl ester.

Claim 10(currently amended): A method or use according to claim 1 ~~any preceding claim~~, in which the EPA is for oral administration in an appropriate pharmaceutical dosage form and is given at a dose between 50mg and 20g/d, preferably between 100mg and 5g/day and very preferably between 300mg and 3g/day.

Claim 11(currently amended): A method or use according to claim 1 ~~any preceding claim~~, in which the EPA is for parenteral, intramuscular or intravenous administration in an appropriate pharmaceutical dosage form.

Claim 12(currently amended): A method or use according to claim 1 ~~any of claims 1 to 10~~ wherein the EPA is added to a nutritional supplement for patient with AN or related disorders, such supplement to be taken orally, or given by enteral tube, or given intravenously.